

Review

Title: Immunologic and neuroinflammatory bases of epileptogenesis: Personalized therapeutic options.

María José Aguilar-Castillo^{1,2,5}, Pablo Cabezudo-García^{1,3,4,5}, Nicolas Lundahl Ciano-Petersen^{1,3,4,5}, Guillermina García-Martin^{1,3,4,5}, Marta Marin-Gracia^{1,4}, Guillermo Estivill-Torrús^{1,3,4,5}, Pedro Jesús Serrano-Castro^{1,3,4,5,6}*

1. Epilepsy Unit. Regional University Hospital of Málaga.
2. Biopathology Service. Regional University Hospital of Málaga.
3. Biomedical Research Institute of Málaga (IBIMA)
4. Neurology Service. Regional University Hospital of Málaga.
5. Andalusian Network for Clinical and Translational Research in Neurology (Neuro-RECA).
6. Department of Medicine. University of Málaga.

* Correspondence: Pedro.serrano.c@uma.es; Tel.: +34 671562365

Abstract: Background: Immunologic and neuro-inflammatory pathways have been found to play a major role in the pathogenesis of many neurological disorders such as epilepsy, proposing the use of novel therapeutic strategies. In the era of personalized medicine and in the face of the exhaustion of anti-seizure therapeutic resources it is worth looking at the current or future possibilities that neuroimmunomodulator or anti-inflammatory therapy can offer us in the management of patients with epilepsy.

Methods: We performed a narrative review on the recent advances on the basic epileptogenic mechanisms related to the activation of immunity or neuroinflammation with special attention to current and future opportunities for novel treatments in epilepsy.

Results: Neuroinflammation can be considered a universal phenomenon and occurs in structural, infectious, post-traumatic, autoimmune, or even genetically based epilepsies. The emerging research developed in recent years has allowed us to identify the main molecular pathways involved in these processes. These molecular pathways could constitute future therapeutic targets for epilepsy.

Conclusions: Different drugs current or in development have demonstrated their capacity to inhibit or modulate molecular pathways involved in the immunologic or neuroinflammatory mechanisms described in epilepsy. Some of them should be tested in the future as possible antiepileptic drugs.

Keywords: Epilepsy. Neuroinflammation. Neuroimmunology. Treatment. Epileptogenesis

1.

1. Introduction

The immunologic and/or neuro-inflammatory substrate has been found to play a role in the pathogenesis of many neurological disorders. In some conditions, they are considered to be a key element (vg demyelinating diseases of the central nervous system [CNS] [1]), while in other they play a secondary role as an adjunct to other mechanisms (vg neurodegenerative diseases [2,3], or other diseases of a genetic or structural basis[4]). This transversal involvement of neuro-inflammation in the pathogenic processes driving, to a greater or lesser extent, all neurological conditions is constantly increasing thanks to major advances in basic research, and epilepsy does not escape from this paradigm.

Classic epidemiological studies labeled a large percentage of epilepsies as idiopathic or of unknown origin [5]. However, nowadays a significant subgroup of these epilepsies are known to have an

immune-mediated origin, to the point that the International League Against Epilepsy (ILAE) classification, in its latest update, recognizes immune-mediated epilepsy as one specific etiological category [6].

Major advances in the characterization of the immune mechanism involved in the pathogenesis of this subset of epilepsies opens a door to the use of novel therapeutic strategies. In the era of personalized medicine, and considering the evident futility of anti-seizure therapeutic against the immune mechanisms of the disease [7], it is worth taking a look at the current or future possibilities that neuroimmunomodulatory or anti-inflammatory therapies may offer to the management of patients with epilepsy.

2. **Material and Methods:**

We performed a narrative review of the state of the matter, including our more recent knowledge related to the following 4 items: the interface between the immune system and the central nervous system (CNS), the mechanisms of immunomediated Epileptogenesis, the epileptic disorders and immunity and the immunomodulatory treatments of epilepsy.

3. **Results**

3.1. **Immune system and its relationship with the central nervous system (CNS)**

Two main components of the immune system have been clearly characterized, known as the innate (non-specific) immune system, and the adaptive (specific) immune system. Their functions and mechanisms are closely linked, and both work synergically against germs or other harmful substances, that occasionally may trigger a self-directed immune response against CNS antigens.

The innate immune system provides a general first-line defense in a non-specific manner, mainly through natural killer cells and phagocytes, but their role within the CNS is poorly defined. However, their equivalent in the CNS is the microglia, which is also considered to play a role in the pathogenesis of several neurological disorders [8].

Conversely, the adaptive immune system is considered a second-line defense, driving a targeted immune response mainly through antigen-specific antibodies. Interestingly, antibodies targeting specific neuronal antigens have also been proved to play a role in the pathogenesis of several neurological immune disorders [9].

In the last two decades, a better characterization of the role that immunity plays in the different morbid processes that affect the CNS disorders has constituted one of the most exciting fields of research in neurology.

The prototype of immune-mediated CNS disease has traditionally been Multiple Sclerosis (MS) and, by extension, demyelinating diseases of both the CNS and the Peripheral Nervous System (PNS). However, today it is known that the clinical relevance of autoimmunity directed against other cellular elements of the brain, such as the cerebral cortex, is far from less than that directed against the white matter and, on the other hand, than the basic processes that mediate the immune reaction in both cases, they are quite homogeneous [10].

The major focus of research has been conditioned by the discovery of multiple autoantibodies directed against specific CNS antigens that have been proposed as diagnostic markers of these diseases. The

target antigens of these antibodies basically include intracellular proteins (cytoplasmic or nuclear enzymes and proteins that act as RNA ligands) and membrane proteins (ion channels and neurotransmitter receptors) [9]. However, also major advances have been made regarding the underlying cellular mechanisms of the immune responses affecting the CNS.

Therefore, it is currently well-known that any pathology of immune-mediated origin of the CNS requires the collaboration of a wide spectrum of immune or inflammatory systems [11].

3.1.1. Peripheral immunity (innate/adaptive) [12]:

The peripheral innate immune response is responsible for elimination of any challenge in a non-specific manner. During this process, it generates inflammatory molecules that activate multiple immune pathways directed to extra and intracellular pathogens [13].

The main effectors of the peripheral innate immune system are neutrophils, monocytes/macrophages, dendritic cells, and natural killer (NK) cells. In addition, native *CD4+ T cells* are the starting point for the transition towards a specific immune response of the adaptive system, and depending on the inflammatory molecules found in their microenvironment, they can further polarize into various cell lines: +

- T helper cells (Th cells): include three cell subtypes: *Th1 cells*, defined by the expression of lineage cytokine interferon (IFN)- γ , required for the control of intracellular viruses and bacteria; *Th2 cells*, defined by the expression of lineage cytokines interleukin (IL)-4/IL-5/IL-13 and the master transcription factor GATA3, which orchestrate the immune reaction against parasites; and *Th17 cells*, defined by the expression of lineage cytokines IL-17/IL-22, important for the immune response against certain extracellular bacteria and fungi., although they also play a major role in the development of autoimmunity.
- Regulatory T cells (Treg cells): This cell subtype accounts for less than 10% of T cell subdivisions. Its immunophenotype is CD4+CD25+Foxp3+, and its main biological function consists of the suppression of self-reactive cells at the peripheral level. The CD25+ marker functionally corresponds to the binding point of the IL-2

Differentiation in one or another cell line is determined by molecular factors produced by antigen-presenting cells and B cells [12,14]:

- IL-12 is necessary for the development of Th1 cells, which are responsible for the production of IFN- γ
- IL-4 induces the development of Th2 cells, which are producers of IL-4, IL-5 and IL-13.
- The combination IL-6 + TGF- β induces the synthesis of Th17 cells, which produce IL-17, IL-22, and IL-23.
- The presence of TGF- β and IL-2, naïve CD4+ T-cells polarize into Treg-cells

The adaptive immune response is specific to the pathogen presented by antigen-presenting cells, which leads to the clonal expansion of T and B lymphocytes. Each clone that originates from the

original T or B lymphocyte has the same antigen receptor as the original and is targeted against the same pathogen or endogenous antigens in case of autoimmunity. In this regard, a field of research has emerged related to the existence of pathogenic autoantibodies against neuronal antigens that cause a broad spectrum of clinical phenotypes by affecting fundamental brain functions [15].

Most of these diseases are the result of an autoimmunization that occurs in the peripheral lymphoid tissue, and one of the most paradigmatic examples are paraneoplastic neurological syndromes (PNS). The main hypothesis on most PNS proposes that an antigen derived from the tumor is presented through the innate immune system to Th cells. Then, pro-inflammatory cytokines subsequently favors the activation of B cells, that produce antigen-specific IgG, as well as memory Treg cells, and CD8+ cytotoxic T cells, especially in case of intracellular antigens [16].

3.1.2. Central innate immunity of the brain:

Traditionally, CNS has been considered an immuno-privileged organ due to the existence of a cellular barrier that surrounds the brain, mainly composed by endothelial cells, pericytes and astrocytes called the Blood-Brain Barrier (BBB), which constitutes a defensive bastion against both cellular and molecular elements from the bloodstream [17].

However, an intrinsic immunity originated in the CNS itself has been identified, termed **central innate immunity** [18], that comprise the following CNS resident immune cells:

- 1.- *Meningeal macrophages*, located in the vicinity of the BBB. They play a main role in immunosurveillance, and subsequently presentation of antigens to CD4+ T cells.
- 2.- *Macrophages near the choroid plexus*. Its basic function is also related to immunosurveillance tasks.
- 3.- *Macrophages of the perivascular space*. They are considered a part of the BBB and participate mostly in immunosurveillance and in the recruitment of circulating leukocytes.
- 4.- *Parenchymal cells: Microglia and astrocytes*. They are considered the key elements of central innate immunity, but also participate in physiological processes regarding brain development and synaptic plasticity.

Microglia is considered the key activator of this type of immunity. Its function includes the monitoring and detection of disturbances in the brain microenvironment and contributes to restoring the homeostasis. In addition to their function as the true "macrophages of the brain", recent studies have shown that they are also critical for ensuring normal brain development and for tissue repair after a noxious stimuli [19]. Microglia recognizes this aggression and respond developing a phenomenon termed "microglial activation", a common process in various pathologies including neuropathic pain, neurodegeneration, and traumatic brain injury [20].

The main recognition systems to these noxious stimuli used by the Microglia are called Innate Immune Receptors. Among them, the most important are Toll-Like-Receptor System (TLR), Nod-Like Receptor System (NLR) and Inflammasome-Associated Nucleotide-Binding Domain, Leucine-Rich Repeat Proteins.

All three are membrane-bound molecular chains that are activated after the recognition and binding with peripheral inflammation effectors, which are the so-called "alarm" molecules, fundamentally:

DAMPs (*Danger Associated Molecular Pattern*) [21] as molecules generated by a heterogeneous group of insults both centrally (Traumatic brain injury, cerebral ischemia) and peripherally (Radiation, metabolic syndrome, Aging [22]); and *PAMPs* (*Pathogens Associated Molecular Pattern*) [23], small molecular fragments derived from different microorganisms, including HIV or SARS-Cov2 [24].

After the binding of these Innate Immune Receptors with their peripheral “alarm” ligand, the result will be a subsequent activation of microglia into two states:

- M1 state or pro-inflammatory state, which converts microglia into a secretory cell of elements such as cytokines (IL-1 β , IL6, TNF α), chemokines (CCL2), and other products such as ROS (Reactive Oxygen Species), NO (Nitric Oxide) or Glutamate, responsible of cell destruction processes of inflammatory origin, also known as pyroptosis [25].
- M2 state or alternative activation, which has the opposite effect, resulting in secretion of anti-inflammatory or neurotrophic factors[26].

Peripheral activators of tissue damage induce the conversion to the M1 state. The outline of the processes described can be seen in Figure 1.




Figure 1. Outline of the processes underlying the activation of microglia [27]. Created with Biorender.com.

Astrocytes also exert a key role in central innate immunity, under the tight regulation of microglia.[28]. It's mainly involved in the control and regulation of immune cells crossing through the BBB.

Under pathological conditions, activated microglia release factors that activate several astrocytic intracellular signaling pathways, such as:

- Mammalian Target of Rapamicin (mTOR) pathway,
- Nuclear Factor k-B (NF- κ B) pathway,

- Janus Kinase (JAK)-Signal transducer,
- Activator of transcription (STAT) pathway, and
- Mitogen-activated protein kinase (MAPK) pathway[8,29].

Subsequently, reactive astrocytes secrete factors that promote changes in BBB permeability, resulting in the recruitment of immune cells into the brain parenchyma, as well as several cytokines, amplifying the initial innate immune response and leading to neuroinflammation. Thus, a constant communication (a dialogue) between microglia and astrocytes is a key element in the maintenance of the innate immune response [30].

In addition, the brain is not exempt from circulating pro-inflammatory elements that cross the BBB in some circumstances, such as aging or metabolic or infectious insults [18]. The latter include both components of peripheral innate immunity (such as macrophages and granulocytes) and T and B cells as part of adaptive immunity (Figure 2).




Figure 2. Types of immunity acting at the level of the CNS. Created with Biorender.com

3.2. Mechanisms of immunomediated epileptogenesis.

3.2.1. Epileptogenesis and peripheral immunity:

The epileptogenicity of the molecules arising from the activation of peripheral innate immunity remains a matter of debate [31].

Recent research studies have shown elevated levels of these molecules in patients with epilepsy. Particularly, a recent systematic review showed that increased levels of IL-1ra, IL-1, IL-6, and CXCL8/IL-8 in several different epilepsy etiologies independently of the etiology [32]. In addition, there is evidence that this elevation is independent of etiology [33].

In the case of post-traumatic epilepsy, many cytokines are released after severe brain injury for days, accompanied by an activation of ion channels and modifications of receptors associated with neuronal

excitation and inhibition. Therefore, microglia and peripheral immunity are activated in hours or days, while neuroinflammation persists for weeks and coincides with neuronal loss. Subsequently, mossy fibers sprouting occurs in the hippocampus contributing to increase neuronal excitability [34]. Our understanding of the mechanisms of epileptogenic related to peripheral adaptive immunity has undergone a radical change thanks to the description and characterization of a new group of autoimmune-based neurological pathologies, that has led to the term autoimmune-based epilepsy [9]. Among Epileptic disorders related to autoimmunity, it is important to distinguish between immune-mediated encephalitis (especially autoimmune limbic encephalitis [ALE]), and autoimmune-associated epilepsy (AAE), a chronic epileptic syndrome with the capacity for spontaneous recurrence of seizures in the long term [35]. Relationship between ALE and the risk of subsequently developing chronic epilepsy remains unclear, and is considered to be mainly related to the nature of the associated neuronal antibody [36]:

- ALE with Autoantibodies against surface antigens: Infrequently associated with oncological pathology and with good response to immunomodulatory treatments [37]. Autoantibodies against surface antigens has epileptogenic capacity per se, but the risk of developing AAE is lower due to the reversible effect of these antibodies after their removal. Table 1 shows a summary of the main Autoantibodies included in this category.

Table 1. Main antibodies against structures with epileptogenic capacity.

Mechanism of action	Autoantibodies	Target
Against Membrane Surface Antigens.	NMDAR GABA _A R GABA _B R AMPA Glycine receptor	Postsynaptic membrane.
Against proteins that stabilize potassium channels.	LGI1 CASPR2	Presynaptic membrane
Against enzymes that catalyze the formation of neurotransmitters	GAD65	Intracellular

- ALE with Autoantibodies against intracytoplasmic antigens: Includes classic paraneoplastic syndromes related to onconeural antibodies. Related AAE is characterized by its refractoriness to medical treatments [38,39]. Table 2.

Antibodies (epitope)	Clinical expression	Associated tumor (>90%)
Yo (CDR2L)	Cerebellar ataxia, Brain stem encephalitis	Ovarian carcinoma (> 60%), Breast carcinoma.

Hu (HuD)	Limbic and Brain stem encephalitis. Peripheral neuropathy.	Oat cell carcinoma of the lung (>75%). Non-oat cell carcinoma of the lung.
Ri (NOVA1)	Limbic and Brain stem encephalitis. Opsoclonus.	Breast carcinoma (>50%). Oat cell carcinoma of the lung.
CV2 (CRMP5)	Encephalomyelitis. Polyneuropathy.	Oat cell carcinoma of the lung (>75%). Thymoma.
Ma1, 2	Limbic and Brain stem encephalitis	Carcinoma of the testicle (50%).
PCA-2 (MAP1B)	Encephalomyelitis. Peripheral neuropathy.	Oat cell carcinoma of the lung. Non-oat cell carcinoma of the lung.
Antiamfifisine	Stiff person syndrome. LE.	Oat cell carcinoma of the lung. Breast carcinoma.
SOX-1	Ataxia. Lambert-Eaton syndrome.	Oat cell carcinoma of the lung (>95%).
GFAP	Meningo-encephalomyelitis.	Ovarian teratoma (35%).
Zic-4	Cerebellar ataxia.	Oat cell carcinoma of the lung.

Table 2. Antibodies directed against intracellular antigens. Modified from [39]

AAE is increasingly recognized as a clinical entity with its own personality, thanks to the discovery of neural autoantibodies in patients with epilepsies of unknown origin. It is a field in evolution, and the percentage of patients with epilepsy of unknown origin in which an autoantibody can be identified is still modest [40].

Finally, although ALE is often associated with specific anti-neuronal antibodies, it is widely known that those targeting intracellular antigens might be merely biomarkers of the disease, sustained by their inability to reproduce the clinical phenotype in animal models and the prominent T cell-mediated nature of the immune response, which is more commonly associated with the development of AAE following ALE due to neuronal loss and gliosis [21].

3.2.2. Epileptogenesis and brain innate immunity:

Recent experimental studies and pathological analyses of brain tissue samples from patients with refractory epilepsy suggest that activation of microglia play a key role in the etiopathology of epilepsy and seizure disorders [41].

Although the increase in biomarkers of neuroinflammation in patients with epilepsy has been known for a long time, some authors argued that they are a consequence of seizures while others defended a primary role in epileptogenesis [31]. The biomarkers that have experimental evidence in animal models for modifying neuronal excitability are:

- **IL-1 Receptor (IL-R1) / Toll-like Receptor (TLR)**[42]: Preclinical investigations in experimental models using pharmacological and genetic tools have identified a significant contribution of interleukin-1 (IL-1) type 1 receptor /Toll-like receptor (IL-1R/TLR) signaling to seizure activity. This signaling can be activated by ligands associated with infections (PAMPS) or by endogenous molecules, such as proinflammatory cytokines (e.g. IL-1beta) or DAMPS (e.g. high-mobility group box 1 (HMGB1))[43].

The activation of the IL-1 β /IL-1 β R axis is strictly linked to the secretion of the intracellular protein MyD88 after the activation of innate immune receptors (especially TLR) during pathogenic recognition [27]. This activates an intracellular molecular cascade that, ultimately, can lead to an alteration of neuronal excitability.

- **TNF- α :** TNF- α affects seizure susceptibility in animal models in a dual pattern. The mechanism of action seems to be exerted through receptors TNFR1 (p55) or TNFR2 (p75) receptor signaling[44]. In general, TNFR1 has been reported to mediate the ictogenic effects of TNF- α , whereas TNFR2 mediates the neuroprotective actions of this cytokine.
- **High-Mobility Proteins (HMGB1):** These molecules are components of chromatin, and are passively released from necrotic cells and actively released by cells that are exposed to deep stress [45]. Recent studies have described models of epilepsy induced by bicuculline and Kainic acid that highlight the nature of HMGB1-TLR4 interactions [46], as well as its role in epileptic recurrence, emphasizing the role of immune-related molecules in epileptogenesis [47].
- **Cyclooxygenase-2 (COX-2):** COX-2 is an enzyme synthesizing prostaglandins (PGs) that has also received attention due to its possible involvement in seizure generation[48]. It seems that the presence of COX-2 facilitates the recurrence of seizures in the hippocampus and may up-regulate P-Glycoprotein at the BBB causing AED resistance[49].

Finally, both in status epilepticus and in acute symptomatic seizures there is activation of microglia and astrocytes. Interestingly, experimental evidence found a release of intraparenchymal inflammatory markers such as IL-1 β , IL-6 and TNF- α in the hippocampus or neocortex [50].

3.3. Epileptic disorders and immunity.

In the previous sections we have described the main immunological and neuroinflammatory substrates that can be identified in epileptic disorders. However, it is important to recognize that these substrates have two differential features:

1. **Universality.** Most epileptic disorders, regardless of their etiology (genetic, structural, autoimmune, infectious, traumatic, etc.) involve to a greater or lesser extent the processes described. This universality suggests that these substrates may become valid therapeutic targets regardless of the etiology.
2. **Not compartmentalized.** We will hardly find a pathology that exclusively affects a type of immunity, and a synergic collaboration between the different immune systems is presumed.

Despite these intrinsic features, and mainly considering the therapeutic orientation, it is interesting to establish a classification of epileptic disorders according to the predominantly associated type of immunity.

3.3.1. Epileptic disorders secondary to systemic autoimmune disease:

3.3.1.1. Primary Antiphospholipid syndrome (APS) or Hughes syndrome: APS is an immune-mediated disorder characterized by pregnancy morbidity and arterial or venous thrombotic events, associated with persistent antiphospholipid antibodies (aPL) including Lupus anticoagulant (LA), Anticardiolipin (aCL) anti- β 2-glycoprotein I antibodies (aB2GPI). Epilepsy has a prevalence of around 6 to 9% in patients with APS [51]. Different mechanisms of epileptogenesis have been proposed in this disease, including aPL-mediated inhibition of GABA receptors, and immune-mediated neuronal damage [52].

3.3.1.2. Epilepsy-associated Systemic Lupus Erythematosus (SLE): SLE is an autoimmune disease in which several organs, tissues, and cells are damaged by adherence to autoantibodies and immune complexes. Anti-DNA antibodies are a subgroup of antinuclear antibodies that can bind to single-stranded DNA, double-stranded DNA, or both and are usually IgM or IgG antibodies. Several recent studies have shown the predominant role central innate immunity in the pathogenesis of this encephalopathies [53].

3.3.1.3. Hashimoto's encephalitis: A classical entity included in the steroid-responsive encephalopathy's whose clinical expression is an epileptic encephalopathy with focal seizures and frequent secondary generalization, associated with anti-thyroid autoantibodies directed against Alpha-enolase, dimethyl-argininase-I and Aldehyde-Reductase-I. However, the pathogenic value of these autoantibodies in epileptogenesis is discussed [54]

3.3.1.4. Encephalopathy associated with gluten-related disease: Although the neurological manifestations of celiac disease usually affect other areas of the brain, it is true that people with celiac disease have an elevated risk of chronic focal epilepsy [55]. Neuropathology usually shows predominant T cell infiltration [56] and activation of humoral immunity with the synthesis of antigliadin antibodies.

3.3.1.5. Encephalopathy associated with vasculitis and Anti-Neutrophilic Cytoplasm antibodies (ANCA): It is a type of vasculitis that rarely produce epileptic seizures in the context of a steroid-responsive encephalopathy [54].

3.3.2. Autoimmune diseases primarily involving CNS

3.3.2.1. ALE: Discussed in the section dedicated to adaptive immunity.

3.3.2.2. AAE: The most frequently detected neuronal antibody is Anti-GAD65, defining a refractory epileptic syndrome with its own personality [57,58]. The neurological Anti-GAD65 syndrome is a heterogeneous disease including Stiff-person spectrum disorders, cerebellar

ataxia, AAE and ALE in isolation or as part of an overlap syndrome. In general, it is a picture with poor response to immunotherapies although in a recent review, epileptic seizures were the manifestation with the best response to long-term immunomodulatory therapy [59].

3.3.2.3. Encephalitis with Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies:

Anti-MOG associated disease is a recently identified autoimmune disorder that occurs in both adults and children as CNS demyelination. However, its clinical presentation includes in more than 20% of cases, epileptic seizures, which is why it should be mentioned in this section [60].

3.3.2.4. Rasmussen encephalitis (RE):

RE is the prototype of an epileptic disease related to the activation of cerebral innate immunity. Neuropathological studies have provided evidence of a progressive immune-mediated process of neuronal damage with prominent inflammation dominated by T cells, microglial activation, microglial nodules, and astrogliosis [61]. The natural history of RE is well known, with progressive cognitive impairment, brain hemi-atrophy and continuous partial epilepsy [62].

3.3.2.5. ALE due to pharmacological inhibition of immune checkpoints:

The development of oncological immunotherapy has led to the emergence of a new category of neurological immune-related adverse events secondary to the pharmacological blockade of immune checkpoints. The clinical expression is very heterogeneous, but a relevant percentage of these patients develop LE. The pathological substrate of these patients is an infiltration of T cells as well as activation of microglia, consistent with a predominance of central innate immunity [63].

In a recent retrospective series that included 63 patients with immune check-point inhibitors related neurologic autoimmunity, 21 (33%) patients whose clinical manifestations included epileptic seizures were described, in most cases related to LE [64]. Seventy-seven percent of these patients had detectable neural-specific autoantibodies, which implies synergic collaboration between the different immune systems. The drugs most frequently implicated in the literature are **Nivolumab**[65–67] and **Pembrolizumab**[68,69].

3.3.3. Epilepsies secondary to structural etiologies with a predominant role of autoimmunity.

3.3.3.1. Hippocampal Sclerosis (HS): In human epilepsy surgical resections as well as in animal models, an involvement of the adaptive immune system was observed in this type of epilepsy. T cell numbers (CD3⁺ as well as CD8⁺) are significantly elevated in HS compared to healthy controls [70]. Secondly, T cell numbers in HS correlated with the degree of neuronal loss.

3.3.3.2. mTORpathies (Structural pathologies secondary to alteration of the mTOR pathway):

3.3.3.2.1. Tuberos Sclerosis Complex (TSC): It is a genetic disease with a predisposition to the development of structural alterations of the cerebral cortex called tubers, as well as neoplasms such as subependymal giant cell astrocytomas (SEGA). The pathogenic mechanism is related to central innate immunity abnormalities, mainly mutations leading to an

hyperactivation of the mTOR pathway. However, an inhibition of this system can be achieved pharmacologically through mTOR inhibitor drugs such as everolimus. This is the first of the genetically based etiologies for which, today, we have a personalized therapeutic strategy that acts directly on the basic mechanisms of epileptogenesis [71].

3.3.3.2.2.Focal Cortical Dysplasia (FCD): Some FCD produce an activation of cerebral innate immunity, mainly microglial activation. Although their exact pathogenesis remains poorly understood, somatic mutations in the mTOR pathway have been found in FCD type IIb [72].

3.4. Immunomodulatory and/or anti-inflammatory treatments in epilepsy.

All the aforementioned evidence opens the door to the emergence of new antiepileptic therapeutic strategies that surpass the classic paradigm of anti-seizure drugs and inaugurates the field of anti-epileptogenic treatment. Some of them have already been used in the history of epilepsy thanks to serendipity, such as steroids or Adrenocorticotrophic hormone (ACTH) for certain catastrophic childhood epilepsies such as West Syndrome [73].

Table 3 summarizes the main therapeutic lines according to the degree of development in clinical research.

Status	Category	Drug	Mechanism of action	Indications
Established	Corticotherapy	Prednisone	Genomic effects at the transcriptional and post-transcriptional level on the molecular pathways that converge on the Nuclear Factor- κ B (NF- κ B)	Infantile spasms
		Prednisolone		West syndrome
		Dexamethasone		LE (First line) SREAT
	Autoantibody removal therapies	IgIV	Remove pathogenic elements from the circulation (vg Autoantibodies or Immunocomplexes) and elimination of proinflammatory Cytokines	LE (Fist line)
		PLEX		RE
	Immunosuppressors	Rituximab	Anti-CD20 monoclonal antibody.	LE (Second line)
		Azathioprine	Antagonist of the synthesis of purines and production of DNA/RNA for the proliferation of white blood cells	LE (Second line) RE
		Cyclophosphamide	Cellular apoptosis through induction of irreversible DNA alterations	LE (Second line)
		Mycophenolate Mofetil	Inhibits proliferation of T and B lymphocytes thereby suppressing cell-mediated immune responses and antibody formation.	LE (Second line)
	m-TOR pathway modulating drugs	Everolimus	m-TOR pathway modulation	TSC FCD (Ongoing clinical trial; NCT03198949)

Ongoing Clinical trials	TNF- α inhibitor drugs	Adalimumab* Infliximab Golimumab Cer- tolizumab pegol	TNF- α Antagonism	RE (Ongoing clinical trial with Adalimumab; NCT04003922) LE (Retrospective open label study with Infliximab)
	T lymphocytes modulating drugs	Natalizumab* Inebilizumab*	Modulation of T-Lymphocytes	Refractory Epilepsy (Phase II clinical trial with Natalizumab; NCT03283371) Anti-NMDAR LE (Ongoing clinical trial with Inebilizumab; NCT04372615)
	Anti-neonatal Fc receptor (FcRn) antibodies	Rozanolixizumab*	IgG catabolism, resulting in reduced overall IgG and pathogenic autoantibody levels	Anti-LG11 LE (Ongoing clinical trial; NCT04875975)
Open label Studies	Cytokines targeted therapies	Anakinra* Tocilizumab* Situximab Emapalumab	Modulation of synthesis of Cytokines	RE (Retrospective studies with Anakinra) FIRES (Retrospective studies with Anakinra and Tocilizumab).
	Proteasome inhibitors	Bortezomib*	Selective inhibitor of the 26S proteasome, preventing the activation of NF- κ B	Anti-NMDAR LE (Retrospective studies).
Animal models	TLR pathway inhibitor drugs	Resveratrol*	Suppresses NF- κ B induced by TLRs 3 and 4	-
	HMGB1 inhibitor drugs	Glycyrrhizin*	Inhibitions of High-Mobility Proteins	-
	Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitor Drugs	Lestaurtinib* AZD1480 Tofacitinib Baricitinib SAR317461 Momelotinib Filgotinib Baricitinib Ruxolitinib Pacritinib	JAK-STAT inhibition	-

NF- κ B inhibitor drugs	Dimethyl-Fumarate* Fingolimod* Teri-flunamide	Inhibition of NF- κ B pathway	-
MAPK pathway inhibitor drugs	SB203580* Macranthoin G PD-0325901	Inhibition of p38-MAPK	-
COX-2 inhibitor drugs	Aspirin* Naproxen* Rofecoxib* Nimesulide*	Cox-2 inhibition	-

3.4.1. Established treatments used in clinical practice:

3.4.1.1. Corticotherapy: Steroid therapy has a powerful anti-neuroinflammatory effect due to its genomic effects at transcriptional and post-transcriptional levels, primary exerted on the molecular pathways that converge into the Nuclear Factor- κ B (NF- κ B)[74], but also prevents microglial activation. It is currently the first-line therapeutic resource in cases of acute onset in the etiologies encompassed within what has been called Steroid-Responsive Encephalopathies (SREAT) such as Hashimoto's encephalitis, paraneoplastic LE, Lupic encephalopathy and Vasculitis-associated encephalopathy with Anti-Neutrophilic Cytoplasm (ANCA) antibodies.

3.4.1.2. Immunoglobulins IV (IVIg)/Plasmapheresis (PLEX): IgIV and PLEX are generally used as complementary treatment of steroids in cases of acute presentation, but also as maintenance treatment in relapses or chronic disorders. In both types of treatments the mechanism of action consists in their ability to block or remove pathogenic elements from the circulation (vg Auto-Antibodies or Immunocomplexes), but also modulating the proliferation of B cells and plasma cells, and production of cytokines [75].

3.4.1.3. Immunosuppressors:

3.4.1.3.1. Rituximab: Anti-CD20 monoclonal antibody used in cases of involvement of adaptive humoral immunity. It is widely used due to its good tolerability and safety. Rituximab can be used as both a second-line agent for acute immunosuppression and as a long-term immunosuppressant for recurrent cases. Rituximab, however, does not deplete antibody-secreting cells which are typically CD20-negative. Therefore, rituximab may work by deleting the antigen specific memory B-cell populations which secrete the pathogenic antibodies [39].

3.4.1.3.2. Azathioprine: It's an antagonist of the synthesis of purines, and consequently, of the production of DNA / RNA for the proliferation of white blood cells. Azathioprine usually takes 6 to 8 months to be effective, so it is often needed along with the progressive and concomitant reduction of oral steroids [9].

3.4.1.3.3. Cyclophosphamide: It induces cellular apoptosis by causing irreversible DNA alterations. It is generally reserved for severe cases refractory to other immunotherapies due to the strong immunosuppressive effect and increased risk of adverse events including nausea and vomiting, alopecia, hemorrhagic cystitis, agranulocytosis, infertility, and increased risk of tumors[76].

3.4.1.3.4. Mycophenolate mofetil: This drug depletes guanosine nucleotides preferentially in T and B lymphocytes, and inhibits their proliferation, thereby suppressing cell-mediated immune responses and antibody synthesis[76].

3.4.1.4. m-TOR pathway modulating drugs: This line of research has produced the first drugs approved for the treatment of some Epileptic disorders of neuroinflammatory basis, such as those included within the Tuberous Sclerosis Complex. **Everolimus** has shown to be effective in the treatment of epilepsy related to Tuberous Sclerosis with level of evidence I [77]. Additionally, there is an ongoing clinical trial of everolimus in type II FCD (ClinicalTrials.gov Identifier: NCT03198949).

3.4.2. Future therapeutic strategies:

Novel immunomodulatory strategies will be developed over the next few years due to the better understanding of the basic mechanism underlying the immunopathogenesis of epilepsy. Therefore, most of the following therapies could be proposed.

Among the drugs modulating the central innate immunity, we will highlight:

3.4.2.1. TLR pathway inhibitor drugs: Research in selective TLR pathway blockade strategy (IL-1 β /IL-1 β Raxis) has generated some molecules that have shown antiepileptic efficacy in animal models. Among them, perhaps the most promising is **Resveratrol**[78].

3.4.2.2. HMGB1 inhibitor drugs: Emerging evidence is suggesting that HMGB1 may contribute to the pathogenesis of epilepsy [46], since **Glycyrrhizin**, an HMGB1 inhibitor, exhibits neuroprotective and antiepileptic effects in different animals models of epilepsy [79,80]. However, this drug has not been assessed in clinical trials for epilepsy.

3.4.2.3. TNF- α inhibitor drugs: There are four TNF- α inhibitors approved as treatments for ulcerative colitis and/or Crohn's disease: **infliximab**, **adalimumab**, **golimumab** and **certolizumab pegol**[81]. The mechanism of action is based on both the neutralization of TNF- α bioactivity and the induction of apoptosis of TNF-expressing mononuclear cells[82]. Adalimumab is a fully human IgG1 monoclonal antibody that specifically binds to TNF- α , which showed to be reduce seizures and functional impairment in patients with RE[83]. Indeed, there is an ongoing clinical trial trying to evaluate the benefit of Adalimumab in patients with RE. (ClinicalTrials.gov Identifier: NCT04003922). In addition, **Infliximab** was effective in a patient with relapsing poly-chondritis and LE [84]. Conversely, **golimumab** and **certolizumab** has been no tested for epilepsy.

3.4.2.4. Drugs modulating T lymphocytes: A large experience has been gathered about these drugs regarding efficacy and safety due to their use as disease modifying therapies in multiple sclerosis.

3.4.2.4.1. Natalizumab is a humanized monoclonal anti- α 4-integrin antibody approved for the treatment of multiple sclerosis. Integrins are heterodimeric proteins expressed on the cell surface of leukocytes that participate in a wide variety of functions, such as survival, growth, differentiation, migration, inflammatory responses, and tumor invasion, among others[85]. Natalizumab interferes with leukocyte migration across the BBB, which is mediated by interaction between α 4-integrin and vascular cell adhesion molecule-1, resulting in a selective CNS immunosuppression due to a lower recruitment of immune cells in the cerebral parenchyma[86]. The administration of anti- α 4-integrin antibodies showed to reduced seizures in a mouse model of epilepsy [87]. However, a recent phase II clinical trial in refractory epilepsy did not meet the primary endpoint of decreasing seizures, although no adverse events were reported [88]. Further exploration of possible anti-inflammatory therapies for drug-resistant epilepsy is warranted[89]. Interestingly, some cases of RE has been successfully treated with **Natalizumab** [90].

3.4.2.4.2. Inebilizumab: this drug is a promising therapeutic monoclonal antibody against the B-cell surface antigen CD19 that recently shown to be safe and efficacious in the treatment of neuromyelitis optica spectrum disorder, another antibody-mediated disorder of the CNS[91]. Compared to rituximab, inebilizumab not only depletes CD20+ B-cells, but also CD20-plasmablasts and plasma cells, resulting in robust and sustained suppression of humoral immunity. There is an ongoing clinical trial phase II with Inebilizumab for the treatment of limbic encephalitis with anti-NMDAR antibodies (ClinicalTrials.gov Identifier: NCT04372615).

3.4.2.5. Cytokine-targeted therapies: Given the central role of cytokines in many Epileptic disorders, these therapies are promising for patients with epilepsy [92]. Among them, we mainly

distinguish anti-interleukin drugs (**Anakinra**, and **Tocilizumab**) and anti-Interferon- γ drugs (**Situximab** and **Emapalumab**).

3.4.2.5.1. **Anakinra**, an anti-IL1 receptor has shown antiepileptic properties in patients with super refractory epileptic status [93], RE[94] and especially in cases of febrile infection-related epilepsy syndrome (FIRES), for which it has been proposed as a first-line therapeutic alternative[95,96]. Additionally, anakinra has shown to reduce seizures in animal models of anti-NMDAR encephalitis and Lithium–Pilocarpine induced-epilepsy.

3.4.2.5.2. **Tocilizumab**, an anti-IL6 receptor, been reported to be effective in FIRES refractory to Anakinra[97].

Currently, there are no research reports with **Situximab** or **Emapalumab** for epilepsy.

3.4.2.6. **Anti-neonatal Fc receptor (FcRn) therapies:** A novel treatment approach targets the neonatal Fc receptor (FcRn) of several immune cells. The primary function of FcRn is to prevent IgG and albumin from lysosomal degradation through the recycling and transcytosis of IgG, therefore, prolonging its half-life. Antagonism of this receptor causes IgG catabolism, resulting in reduced overall IgG and pathogenic autoantibody levels[98]. There is currently an ongoing Phase II Clinical Trial with **Rozanolixizumab** (ClinicalTrials.gov Identifier: NCT04875975), a high-affinity human neonatal FC receptor (IgG4P) monoclonal antibody (IgG4P), developed to reduce pathogenic IgG in autoimmune and alloimmune diseases, such as encephalitis with Anti-LGI1 antibodies.

3.4.2.7. **Proteasome inhibitors:** Drugs targeting long lived plasma cells (LLPCs) are a promising treatment for antibody-mediated neurological conditions. Specifically, **Bortezomid** is a selective inhibitor of the S26 proteasome for which a possible efficacy has been suggested for the treatment of Limbic Encephalitis with Anti-NMDA antibodies. A recent systematic review shows that more than 50% of the patients reported in the literature treated in this way showed improvement. In any case, specifically designed studies are necessary to evaluate this topic [99].

3.4.2.8. **Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitors:** Inhibitors of the JAK-STAT pathway are proposed as a future therapeutic target in neuroinflammatory-based processes, since they modulate the intracellular signaling pathways of multiple cytokine receptors[100]. Among these molecules we find **AZD1480**, **Tofacitinib**, **Baricitinib**, **SAR317461**, **Momelotinib**, **Filgotinib**, **Baricitinib**, **Ruxolitinib**, **Lestaurtinib** or **Pacritinib** [101], although **Lestaurtinib** has any promising studies on animal models of epilepsy [102].

3.4.2.9. **NF- κ B inhibitors:** As mentioned before, steroids preferentially and indirectly act on the NF- κ B transcription complex, although other novel drugs may selectively block this relevant pathway of Neuroinflammation. Among them, **Dimethyl-Fumarate, Fingolimod or Teriflunamide** have been widely used in patients with multiple sclerosis [103]. Interestingly, promising results have been reported on animal models of epilepsy treated with **Dimethyl-Fumarate** and **Fingolimod** [104,105]. Emerging experimental findings suggest that **Fingolimod** exerts disease-modifying anti-epileptic effects based on its anti-neuroinflammatory properties, potent neuroprotection, anti-gliotic effects, myelin protection, reduction of mTOR signaling pathway and activation of microglia and astrocytes. Thus, the antiepileptic efficacy of this drug seems to be supported by various mechanisms of action that converge on the modulation of innate brain immunity[105,106].

3.4.2.10. **MAPK pathway inhibitors :** Several drugs perform a selective blockade of this pathway, such as **SB203580**[107], **Macranthoin G** and **PD-0325901** (a derivative of CI-1040). The Inhibition of p38-MAPK by SB203580 may regulate epileptic activity by decreasing expression levels of Adenosine A1 receptor (A1R) and the type 1 equilibrative nucleoside transporter (ENT1) in animal models[107,108].

3.4.2.11. **COX-2 inhibitor drugs:** COX-2 inhibitors have shown anti-seizure properties in various acute and chronic models of epilepsy. **Aspirin, naproxen, rofecoxib, or nimesulide** protected mice from mortality caused by Pentylentetrazol Induced Seizure (PTZ) [109].

4. Conclusions

The avalanche of novel evidence unraveling the pathogenesis of neuroinflammatory and/or neuroimmunological mechanisms driving many epileptic disorders has broadened the possibility of testing novel unexplored therapies. Several drugs have demonstrated their capacity to inhibit or modulate molecular pathways involved in these immune mechanisms. However, while some therapies such as everolimus have already demonstrated antiepileptic activity in humans, most novel therapies have only suggested their ability to improve seizures in in-vitro or animal models, and further studies should assess their potential as antiepileptic drugs.

These therapeutic strategies may lead to a paradigm shift in the treatment of epilepsy, enabling a true antiepileptic treatment targeting the pathogenic basis of the disease. Future studies assessing the efficacy and safety of these therapies in patients with epilepsy are warranted.

Author Contributions: Conceptualization, MJAC, PJSC, GET and NLCP; methodology, MJAC, PCG, GGM and MMG; writing—original draft preparation, MJAC, PJSC and NLCP.; writing—review and

editing, MJAC, NLCP and PJSC.; supervision, PJSC.; funding acquisition, PJSC. All authors have read and agreed to the published version of the manuscript.”

Funding: This research was funded by Andalusian Network of Clinical and Translational Research in Neurology (Neuro-RECA) of the Consejería de Salud y Familias de la Junta de Andalucía (Code: RIC-0111-2019).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

- 1 Nylander A, Hafler DA. Multiple sclerosis. *J Clin Invest*. 2012;122(4). DOI: 10.1172/JCI58649.1180
- 2 Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. *Alzheimer’s Dement*. 2016 Jun;12(6):719–32.
- 3 Wesselingh R, Butzkueven H, Buzzard K, Tarlinton D, O’Brien TJ, Monif M, et al. Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle? *Front Immunol*. 2019 Sep;10(September):1–14.
- 4 Yang H, Wang X, Zhang Y, Liu H, Liao J, Shao K, et al. Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity. *J Cell Physiol*. 2014 Jan;229(1):17–26.
- 5 Sander JW, Shorvon SD. Epidemiology of the epilepsies. *J Neurol Neurosurg Psychiatry*. 1996 Nov;61(5):433–43.
- 6 Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):522–30.
- 7 Löscher W. The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments. *Neuropharmacology*. 2020 May;167. DOI: 10.1016/j.neuropharm.2019.04.011
- 8 Kölliker-Frers R, Udovin L, Otero-Losada M, Kobienc T, Herrera MI, Palacios J, et al. Neuroinflammation: An Integrating Overview of Reactive-Neuroimmune Cell Interactions in Health and Disease. *Mediators Inflamm*. 2021;2021. DOI: 10.1155/2021/9999146
- 9 Sechi E, Flanagan E. Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. *Front Neurol*. 2021 Jul;12:673339.
- 10 Waisman A, Liblau R, Becher B. Innate and adaptive immune responses in the CNS. *Lancet Neurol*. 2015 Sep;14(9):945–55.
- 11 Gendelman H. Neural immunity: Friend or foe? *J Neurovirol*. 2002 Dec;8(6):474–9.
- 12 Huang X, Hussain B, Chang J. Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms. 2021. DOI: 10.1111/cns.13569

-
- 13 Le Page A, Dupuis G, Frost EH, Larbi A, Pawelec G, Witkowski JM, et al. Role of the peripheral innate immune system in the development of Alzheimer's disease. *Exp Gerontol.* 2018 Jul;107(July 2017):59–66.
 - 14 van Hamburg JP, de Bruijn MJW, Ribeiro de Almeida C, van Zwam M, van Meurs M, de Haas E, et al. Enforced expression of GATA3 allows differentiation of IL-17-producing cells, but constrains Th17-mediated pathology. *Eur J Immunol.* 2008;38(9):2573–86.
 - 15 Alexopoulos H, Dalakas MC. The immunobiology of autoimmune encephalitides. *J Autoimmun.* 2019;104(September):102339.
 - 16 Iorio R, Lennon V a. Neural antigen-specific autoimmune disorders. *Immunol Rev.* 2012 Jul;248(1):104–21.
 - 17 Melzer N, Meuth SG, Wiendl H. Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options. *Curr Opin Neurol.* 2012 Jun;25(3):341–8.
 - 18 Healy LLM, Yaqubi M, Ludwin S, Antel JJP. Species differences in immune-mediated CNS tissue injury and repair: A (neuro)inflammatory topic. *Glia.* 2020 Apr;68(4):811–29.
 - 19 Michell-Robinson MA, Touil H, Healy LM, Owen DR, Durafourt BA, Bar-Or A, et al. Roles of microglia in brain development, tissue maintenance and repair. *Brain.* 2015;138(5):1138–59.
 - 20 Ní Chasaide C, Lynch MA. The role of the immune system in driving neuroinflammation. *Brain Neurosci Adv.* 2020 Jan;4:239821281990108.
 - 21 Tan TH, Perucca P, O'Brien TJ, Kwan P, Monif M. Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease. *Epilepsia.* 2020 Dec;epi.16788.
 - 22 Feldman N, Rotter-Maskowitz A, Okun E. DAMPs as mediators of sterile inflammation in aging-related pathologies. *Ageing Res Rev.* 2015;24:29–39.
 - 23 Aguilera G, Colín-González AL, Rangel-López E, Chavarría A, Santamaría A. Redox Signaling, Neuroinflammation, and Neurodegeneration. *Antioxidants Redox Signal.* 2018;28(18):1626–51.
 - 24 Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, Antonio Reyes-Bueno J, Petersen NC, Aguilar-Castillo MJ, et al. Influencia de la infección SARS-Cov2 sobre Enfermedades Neurodegenerativas y Neuropsiquiátricas: ¿Una pandemia demorada? *Neurología.* 2020 Apr [cited 2020 Apr 20]. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0213485320300670>
 - 25 Mészáros Á, Molnár K, Nógrádi B, Hernádi Z, Nyúl-Tóth Á, Wilhelm I, et al. Neurovascular Inflammaging in Health and Disease. *Cells.* 2020;9(7):1–23.
 - 26 Muzio L, Viotti A, Martino G. Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy. *Front Neurosci.* 2021;15(September). DOI: 10.3389/fnins.2021.742065
 - 27 Subramaniam SRS, Federoff HJH. Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease. *Front Aging Neurosci.* 2017 Jun;9(JUN):176.
 - 28 Wohleb ES, Godbout JP. Basic aspects of the immunology of neuroinflammation. *Inflammation in Psychiatry.* S. Karger

- AG; 2013; pp 1–19.
- 29 Dhapola R, Hota SS, Sarma P, Bhattacharyya A, Medhi B, Reddy DHK. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer's disease. *Inflammopharmacology*. 2021 Dec;29(6):1669–81.
- 30 Jha MK, Jo M, Kim JH, Suk K. Microglia-Astrocyte Crosstalk: An Intimate Molecular Conversation. *Neuroscientist*. 2019;25(3):227–40.
- 31 Sinha S, Patil SA, Jayalekshmy V, Satishchandra P. Do cytokines have any role in epilepsy? *Epilepsy Res*. 2008;82(2–3):171–6.
- 32 de Vries EE, van den Munckhof B, Braun KPJ, van Royen-Kerkhof A, de Jager W, Jansen FE. Inflammatory mediators in human epilepsy: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2016;63:177–90.
- 33 Alvim M, Morita-Sherman M, Yasuda C, Rocha N, Vieira É, Pimentel-Silva L, et al. Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology. *Epilepsia*. 2021 Jul;epi.17023.
- 34 Webster KM, Sun M, Crack P, O'Brien TJ, Shultz SR, Semple BD. Inflammation in epileptogenesis after traumatic brain injury. *J Neuroinflammation*. 2017 Jan;14(1). DOI: 10.1186/s12974-016-0786-1
- 35 Steriade C, Britton J, Dale RC, Gadoth A, Irani SR, Linnoila J, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. *Epilepsia*. 2020;61(7):1341–51.
- 36 Chen L, Zhu L, Lu D, Dai S, Han Y, Wu Z, et al. Association between autoimmune encephalitis and epilepsy: Systematic review and meta-analysis. *Seizure*. 2021 Oct;91:346–59.
- 37 Romoli M, Krashia P, Sen A, Franciotta D, Gastaldi M, Nobili A, et al. Hippocampal epileptogenesis in autoimmune encephalitis. *Ann Clin Transl Neurol*. 2019;6(11):2261–9.
- 38 Bien CG, Scheffer IE. Autoantibodies and epilepsy. *Epilepsia*. 2011 May;52 Suppl 3(2):18–22.
- 39 Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: Proposed best practice recommendations for diagnosis and acute management. *J Neurol Neurosurg Psychiatry*. 2021 Mar;92(7):757–68.
- 40 Cabezudo-García P, Mena-Vázquez N, Ciano-Petersen NL, García-Martín G, Estivill-Torrús G, Serrano-Castro PJ. Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis. *Brain Sci* 2021, Vol 11, Page 392. 2021 Mar;11(3):392.
- 41 Zhao H, Zhu C, Huang D. Microglial activation: an important process in the onset of epilepsy. *Am J Transl Res*. 2018;10(9):2877–89.
- 42 Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. *Brain Behav Immun*. 2011 Oct;25(7):1281–9.
- 43 Maroso M, Balosso S, Ravizza T, Liu J, Bianchi ME, Vezzani A. Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: The importance of IL-1beta and high-mobility group box 1. *Journal of Internal Medicine*. *J Intern Med*; 2011;

- pp 319–26.
- 44 Balosso S, Ravizza T, Aronica E, Vezzani A. The dual role of TNF- α and its receptors in seizures. *Exp Neurol*. 2013 Sep;247:267–71.
- 45 Wang S, Guan Y, Li T. The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy. *Curr Drug Targets*. 2021 Jul;22(2):171–82.
- 46 Paudel YN, Semple BD, Jones NC, Othman I, Shaikh MF. High mobility group box 1 (HMGB1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches. *J Neurochem*. 2019 Dec;151(5):542–57.
- 47 Matin N, Tabatabaie O, Falsaperla R, Lubrano R, Pavone P, Mahmood F, et al. Epilepsy and innate immune system: A possible immunogenic predisposition and related therapeutic implications. *Hum Vaccin Immunother*. 2015 Jan;11(8):2021–9.
- 48 Rawat C, Kukal S, Dahiya UR, Kukreti R. Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. *J Neuroinflammation*. 2019 Oct;16(1):197.
- 49 Łukawski K, Czuczwar SJ. Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it. *Expert Opin Drug Metab Toxicol*. 2021;17(9):1075–90.
- 50 Reddy D, Kuruba R. Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. *Int J Mol Sci*. 2013 Sep;14(9):18284–318.
- 51 Leal Rato M, Bandeira M, Romão VC, Aguiar de Sousa D. Neurologic Manifestations of the Antiphospholipid Syndrome — an Update. *Curr Neurol Neurosci Rep*. 2021;21(8). DOI: 10.1007/s11910-021-01124-z
- 52 Noureldine MHA, Harifi G, Berjawi A, Haydar AA, Nader M, Elnawar R, et al. Hughes syndrome and epilepsy: When to test for antiphospholipid antibodies? *Lupus*. 2016;25(13):1397–411.
- 53 Ma C, Xia Y, Yang Q, Zhao Y. The contribution of macrophages to systemic lupus erythematosus. *Clin Immunol*. 2019 Oct;207:1–9.
- 54 Xu X, Lin A, Wang X. Seizures in steroid-responsive encephalopathy. *Neurol Sci*. 2021 Feb;42(2):521–30.
- 55 Julian T, Hadjivassiliou M, Zis P. Gluten sensitivity and epilepsy: a systematic review. *J Neurol*. 2019;266(7):1557–65.
- 56 Rouvroye M, Zis P, Dam A Van, Rozemuller A, Bouma G, Hadjivassiliou M. The Neuropathology of Gluten-Related Neurological Disorders: A Systematic Review. *Nutrients*. 2020 Mar;12(3). DOI: 10.3390/NU12030822
- 57 Daif A, Lukas R V., Issa NP, Javed A, VanHaerents S, Reder AT, et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. *Epilepsy Behav*. 2018;80:331–6.
- 58 Fredriksen JR, Carr CM, Koeller KK, Verdoorn JT, Gadoth A, Pittock SJ, et al. MRI findings in glutamic acid decarboxylase associated autoimmune epilepsy. *Neuroradiology*. 2018;60(3):239–45.
- 59 Budhram A, Sechi E, Flanagan E, Dubey D, Zekeridou A, Shah S, et al. Clinical spectrum of high-titre GAD65 antibodies. *J Neurol Neurosurg Psychiatry*. 2021 Jun;92(6):645–54.

-
- 60 Shen C, Zheng Y, Cai M, Yang F, Fang W, Zhang Y, et al. Seizure occurrence in myelin oligodendrocyte glycoprotein antibody-associated disease: A systematic review and meta-analysis. *Mult Scler Relat Disord*. 2020 Jul;42. DOI: 10.1016/J.MSARD.2020.102057
- 61 Aronica E, Mühlebner A, E A, A M. Neuropathology of epilepsy. *Handb Clin Neurol*. 2018;145(1):193–216.
- 62 Bien C, Widman G, Urbach H, Sassen R. The natural history of Rasmussen’s encephalitis. *Brain a J Neurol*. 2002 [cited 2013 Apr 14]. ;125:1751–9.
- 63 Velasco R, Villagrán M, Jové M, Simó M, Vilariño N, Alemany M, et al. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review. *JAMA Neurol*. 2021;78(7):864–73.
- 64 Sechi E, Markovic SN, McKeon A, Dubey D, Liewluck T, Lennon VA, et al. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes. *Neurology*. 2020 Oct;95(17):e2442–52.
- 65 Maniscalco GT, Zekeridou A, Allegorico L, Ranieri A, Napolitano M, Pezzella M, et al. GAD65 autoimmunity after treatment with nivolumab: a multifocal presentation. *Neurol Sci*. 2021 Oct;42(10):4289–91.
- 66 Erol-Yıldız R, Kızılay T, Tüzün E, Mısırlı H, Türkoğlu R. Nivolumab-induced autoantibody negative limbic encephalitis in a patient with Hodgkin lymphoma. *Leuk Lymphoma*. 2020 May;61(6):1519–21.
- 67 Chung M, Jaffer M, Verma N, Mokhtari S, Ramsakal A, Peguero E. Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. *J Neurol*. 2020 Apr;267(4):1023–5.
- 68 Brown MP, Hissaria P, Hsieh AH, Kneebone C, Vallat W. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. *J Neuroimmunol*. 2017 Apr;305:16–8.
- 69 Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. *BMJ Case Rep*. 2016 Mar;2016. DOI: 10.1136/bcr-2016-215012
- 70 Tröscher AR, Sakaraki E, Mair KM, Köck U, Racz A, Borger V, et al. T cell numbers correlate with neuronal loss rather than with seizure activity in medial temporal lobe epilepsy. *Epilepsia*. 2021 Jun;62(6):1343–53.
- 71 Mcdaniel SS, Wong M. Therapeutic role of mamalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. *Neurosci Lett*. 2011;497(3):231–9.
- 72 Zimmer T, Broekaart D, Luinenburg M, Mijnsbergen C, Anink J, Sim N, et al. Balloon cells promote immune system activation in focal cortical dysplasia type 2b. *Neuropathol Appl Neurobiol*. 2021;Ahead of p. DOI: 10.1111/NAN.12736
- 73 SOREL L, DUSAUCY-BAULOYE A. A propos de 21 cas d’hypsarhythmia de Gibbs; son traitement spectaculaire par l’ACTH. *Acta Neurol Psychiatr Belg*. 1958 Feb [cited 2021 Dec 30]. ;58(2):130–41.
- 74 Hwang CJ, Choi D, Park M, Hong J. NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease. *CNS Neurol Disord Drug Targets*. 2019 Aug;18(1):3–10.
- 75 Reeves HM, Winters JL. The mechanisms of action of plasma exchange. *Br J Haematol*. 2014;164(3):342–51.
- 76 Alamilla-Sanchez ME, Alcalá-Salgado MA, Alonso-Bello CD, Fonseca-Gonzalez GT. Mechanism of Action and Efficacy

- of Immunosuppressors in Lupus Nephritis. *Int J Nephrol Renovasc Dis.* 2021 Dec;Volume 14:441–58.
- 77 Krueger D a., Wilfong A a., Holland-Bouley K, Anderson AE, Agricola K, Tudor C, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. *Ann Neurol.* 2013;74:679–87.
- 78 Siddiqui MA, Akhter J, Aarzo, Junaid Bashir D, Manzoor S, Rastogi S, et al. Resveratrol loaded nanoparticles attenuate cognitive impairment and inflammatory markers in PTZ-induced kindled mice. *Int Immunopharmacol.* 2021 Dec;101(Pt A). DOI: 10.1016/j.intimp.2021.108287
- 79 Li Y jun, Wang L, Zhang B, Gao F, Yang CM. Glycyrrhizin, an HMGB1 inhibitor, exhibits neuroprotective effects in rats after lithium-pilocarpine-induced status epilepticus. *J Pharm Pharmacol.* 2019 Mar;71(3):390–9.
- 80 Paudel YN, Khan SU, Othman I, Shaikh MF. Naturally Occurring HMGB1 Inhibitor, Glycyrrhizin, Modulates Chronic Seizures-Induced Memory Dysfunction in Zebrafish Model. *ACS Chem Neurosci.* 2020;12(18). DOI: 10.1021/acschemneuro.0c00825
- 81 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. *Therap Adv Gastroenterol.* 2021 Jan;14:175628482110599.
- 82 Vena GA, Cassano N. Drug focus: Adalimumab in the treatment of moderate to severe psoriasis. *Biol Targets Ther.* 2007 [cited 2021 Dec 24]. ;1(2):93–103.
- 83 Lagarde S, Villeneuve N, Trébuchon A, Kaphan E, Lepine A, McGonigal A, et al. Anti-tumor necrosis factor alpha therapy (adalimumab) in Rasmussen’s encephalitis: An open pilot study. *Epilepsia.* 2016 Jun;57(6):956–66.
- 84 Kondo T, Fukuta M, Takemoto A, Takami Y, Sato M, Takahashi N, et al. Limbic encephalitis associated with relapsing polycondritis responded to infliximab and maintained its condition without recurrence after discontinuation: A case report and review of the literature. *Nagoya J Med Sci.* 2014;76(3–4):361–8.
- 85 Ferreira EFB, Silva LB, Cruz J V., Araújo PHF, Kimani NM, Leite FHA, et al. An Overview of the $\alpha 4\beta 1$ Integrin and the Potential Therapeutic Role of its Antagonists. *Curr Med Chem.* 2021 Feb;28(29):5884–95.
- 86 Miller JW. Inflammation as a Target for Epilepsy Therapy. *Neurology.* 2021;97(18):845–6.
- 87 Fabene PF, Mora GN, Martinello M, Rossi B, Merigo F, Ottoboni L, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. *Nat Med.* 2008 Dec;14(12):1377–83.
- 88 French JA, Cole AJ, Faught E, Theodore WH, Vezzani A, Liow K, et al. Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy. *Neurology.* 2021 Nov;97(18):e1757–67.
- 89 Melvin J, Hardison HH. Immunomodulatory treatments in epilepsy. *Semin Pediatr Neurol.* 2014 Sep;21(3):232–7.
- 90 Bittner S, Simon O, Göbel K, Bien C, Meuth S, Wiendl H. Rasmussen encephalitis treated with natalizumab. *Neurology.* 2013 Jul;81(4):395–7.
- 91 M R, A Z, MA M, D C, D S, J D, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ≥ 4 years in the N-MOmentum trial. *Mult Scler.* 2021 Oct;135245852110472.

-
- 92 Fajgenbaum DC, June CH. Cytokine Storm. *N Engl J Med*. 2020;383(23):2255–73.
- 93 Choi C, Ma S, Ma K, Leung H, Mok V. Super-refractory status epilepticus in autoimmune encephalitis treated with interleukin-1 receptor antagonist, anakinra. *Epileptic Disord*. 2021 Jun;23(3):500–5.
- 94 Mochol M, Taubøll E, Sveberg L, Tennøe B, Olsen KB, Heuser K, et al. Seizure control after late introduction of anakinra in a patient with adult onset Rasmussen's encephalitis. *Epilepsy Behav reports*. 2021 Jan;16. DOI: 10.1016/J.EBR.2021.100462
- 95 Yamanaka G, Ishida Y, Kanou K, Suzuki S, Watanabe Y, Takamatsu T, et al. Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy. *Int J Mol Sci*. 2021 Jun;22(12). DOI: 10.3390/IJMS22126282
- 96 Koh S, Wirrell E, Vezzani A, Nabbut R, Muscal E, Kaliakatsos M, et al. Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): A Report from FIRES workshop. *Epilepsia Open*. 2021 Mar;6(1):62–72.
- 97 Stredny C, Case S, Sansevere A, Son M, Henderson L, Gorman M. Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES). *Child Neurol open*. 2020 Jan;7:2329048X2097925.
- 98 Gable KL, Guptill JT. Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis. *Front Immunol*. 2020 Jan;10:3052.
- 99 Dinoto A, Cheli M, Bratina A, Sartori A, Manganotti P. Bortezomib in anti-N-Methyl-D-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review. *J Neuroimmunol*. 2021 Jul;356. DOI: 10.1016/j.jneuroim.2021.577586
- 100 Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. *Autoimmun Rev*. 2019;18(11):102390.
- 101 Nailwal N, Doshi G. Role of intracellular signaling pathways and their inhibitors in the treatment of inflammation. *Inflammopharmacology*. 2021 Jun;29(3):617–40.
- 102 Medlej Y, Salah H, Wadi L, Saad S, Bashir B, Allam J, et al. Lestaurtinib (CEP-701) modulates the effects of early life hypoxic seizures on cognitive and emotional behaviors in immature rats. *Epilepsy Behav*. 2019 Mar;92:332–40.
- 103 Ambrosius B, Gold R, Chan A, Faissner S. Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy. *Neurol Neuroimmunol NeuroInflammation*. 2019;6(3):1–7.
- 104 Singh N, Saha L, Kumari P, Singh J, Bhatia A, Banerjee D, et al. Effect of dimethyl fumarate on neuroinflammation and apoptosis in pentylenetetrazol kindling model in rats. *Brain Res Bull*. 2019 Jan;144:233–45.
- 105 Bascuñana P, Möhle L, Brackhan M, Pahnke J. Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis. *Drugs R D*. 2020 Sep;20(3):197–207.
- 106 Paudel YN, Angelopoulou E, Piperi C, Gnatkovsky V, Othman I, Shaikh MF. From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod. *Curr Neuropharmacol*. 2020 Apr;18(11):1126–37.
- 107 Tai TY, Warner LN, Jones TD, Jung S, Concepcion FA, Skyrud DW, et al. Antiepileptic action of c-Jun N-terminal kinase

- (JNK) inhibition in an animal model of temporal lobe epilepsy. *Neuroscience*. 2017 May;349:35–47.
- 108 ZHOU X, CHEN Q, HUANG H, ZHANG J, WANG J, CHEN Y, et al. Inhibition of p38 MAPK regulates epileptic severity by decreasing expression levels of A1R and ENT1. *Mol Med Rep*. 2020 Dec;22(6):5348–57.
- 109 Dhir A. An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders. *Expert Opin Investig Drugs*. 2019 Feb;28(2):191–205.